DEPO PROVERA BIBLIOGRAPHY

1. Alvarez-Sanchez F, Brache V, Faundes A. Recent experience with and future directions of contraceptive implants and injectable contraceptives. Curr Opin Obstet Gynecol. Dec 1993;5(6):805-814.
Link to PubMed

2. Archer B, Irwin D, Jensen K, Johnson ME, Rorie J. Depot medroxyprogesterone. Management of side-effects commonly associated with its contraceptive use. J Nurse Midwifery. Mar-Apr 1997;42(2):104-111.
Link to PubMed

3. Baeten JM, Nyange PM, Richardson BA, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol. Aug 2001;185(2):380-385.
Link to PubMed

4. Bahamondes L, Del Castillo S, Tabares G, Arce XE, Perrotti M, Petta C. Comparison of weight increase in users of depot medroxyprogesterone acetate and copper IUD up to 5 years. Contraception. Oct 2001;64(4):223-225.
Link to PubMed

5. Bahamondes L, Trevisan M, Andrade L, et al. The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera. Contraception. Jul 2000;62(1):23-27.
Link to PubMed     

6. Bigrigg A, Evans M, Gbolade B, et al. Depo Provera. Position paper on clinical use, effectiveness and side effects. Br J Fam Plann. Jul 1999;25(2):69-76.
Link to PubMed

7. Borgatta L. Managing clinical complexities of long-term contraception. Medscape Womens Health. Jan 1998;3(1):3.
Link to PubMed

8. Borgatta L, Murthy A, Chuang C, Beardsley L, Burnhill MS. Pregnancies diagnosed during Depo-Provera use. Contraception. Sep 2002;66(3):169-172.
Link to PubMed

9. Canto De Cetina TE, Canto P, Ordonez Luna M. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. Contraception. Mar 2001;63(3):143-146.
Link to PubMed

10. Canto de Cetina TE, Luna MO, Cetina Canto JA, Bassol S. Menstrual pattern and lipid profiles during use of medroxyprogesterone acetate and estradiol cypionate and NET-EN (200 mg) as contraceptive injections. Contraception. Feb 2004;69(2):115-119.
Link to PubMed

11. Chilvers CE. Depot medroxyprogesterone acetate and breast cancer. A review of current knowledge. Drug Saf. Sep 1996;15(3):212-218.
Link to PubMed

12. Chotnopparatpattara P, Taneepanichskul S. Use of depot medroxyprogesterone acetate in Thai adolescents. Contraception. Sep 2000;62(3):137-140.
Link to PubMed

13. Connor PD, Tavernier LA, Thomas SM, Gates D, Lytton SM. Determining risk between Depo-Provera use and increased uterine bleeding in obese and overweight women. J Am Board Fam Pract. Jan-Feb 2002;15(1):7-10.
Link to PDF

14. Cromer BA, Berg-Kelly KS, Van Groningen JP, Seimer BS, Ruusuvaara L. Depot medroxyprogesterone acetate (Depo-Provera) and levonorgestrel (Norplant) use in adolescents among clinicians in Northern Europe and the United States. J Adolesc Health. Aug 1998;23(2):74-80.
Link to PubMed

15. Cromer BA, Lazebnik R, Rome E, et al. Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. Am J Obstet Gynecol. Jan 2005;192(1):42-47.
Link to PubMed

16. Davidson AR, Kalmuss D, Cushman LF, Romero D, Heartwell S, Rulin M. Injectable contraceptive discontinuation and subsequent unintended pregnancy among low-income women. Am J Public Health. Sep 1997;87(9):1532-1534.
Link to PubMed

17. Davis AJ. Use of depot medroxyprogesterone acetate contraception in adolescents. J Reprod Med. May 1996;41(5 Suppl):407-413.
Link to PubMed

18. Diab KM, Zaki MM. Contraception in diabetic women: comparative metabolic study of Norplant, depot medroxyprogesterone acetate, low dose oral contraceptive pill and CuT380A. J Obstet Gynaecol Res. Feb 2000;26(1):17-26.
Link to PubMed

19. Draper B, Morroni C, Hoffman M, Smit J, Beksinska M, JP H. Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception. The Cochrane Database of Systematic Reviews 2005(2):CD005214.
Link to Cochrane Library

20. Earl DT, David DJ. Depo-Provera: an injectable contraceptive. Am Fam Physician. Mar 1994;49(4):891-894, 897-898.
Link to PubMed

21. Enk L, Landgren BM, Lindberg UB, Silfverstolpe G, Crona N. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Horm Metab Res. Feb 1992;24(2):85-89.
Link to PubMed

22. Ertopcu K, Inal MM, Ozelmas I. Demographic analysis of post-abortive and interval-administered hormonal contraceptive methods. Eur J Contracept Reprod Health Care. Mar 2005;10(1):1-5.
Link to PubMed

23. Fraser IS, Dennerstein GJ. Depo-Provera use in an Australian metropolitan practice. Med J Aust. May 2 1994;160(9):553-556.
Link to PubMed

24. Frederiksen MC. Depot medroxyprogesterone acetate contraception in women with medical problems. J Reprod Med. May 1996;41(5 Suppl):414-418.
Link to PubMed

25. Garza-Flores J, Hall PE, Perez-Palacios G. Long-acting hormonal contraceptives for women. J Steroid Biochem Mol Biol. 1991;40(4-6):697-704.
Link to PubMed

26. Goldberg AB, Cardenas LH, Hubbard AE, Darney PD. Post-abortion depot medroxyprogesterone acetate continuation rates: a randomized trial of cyclic estradiol. Contraception. Oct 2002;66(4):215-220.
Link to PubMed

27. Gupta M. Medroxyprogesterone acetate [Depo Provera] injections. Development of striae. Br J Fam Plann. Apr 2000;26(2):104-105.
Link to PubMed

28. Haefner HK, Elkins TE. Contraceptive management for female adolescents with mental retardation and handicapping disabilities. Curr Opin Obstet Gynecol. Dec 1991;3(6):820-824.
Link to PubMed

29. Hampton AL, Nie G, Salamonsen LA. Progesterone analogues similarly modulate endometrial matrix metalloproteinase-1 and matrix metalloproteinase-3 and their inhibitor in a model for long-term contraceptive effects. Mol Hum Reprod. Apr 1999;5(4):365-371.
Link to PDF

31. Heber KR. Medroxyprogesterone acetate as an injectable contraceptive. Aust Fam Physician. Mar 1988;17(3):199-201, 204.
Link to PubMed

32. Hickey M, Fraser I. The contraceptive use of depot medroxyprogesterone acetate. Clin Obstet Gynecol. Dec 1995;38(4):849-858.
Link to PubMed

33. Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception. Oct 2004;70(4):269-275.
Link to PubMed

34. Jarman H, Kovacs GT, Westcott M. Depo Provera: a profile of current users. Aust N Z J Obstet Gynaecol. Feb 1990;30(1):74-76.
Link to PubMed

35. Kaunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med. May 1996;41(5 Suppl):419-427.
Link to PubMed

36. Kaunitz AM. Current options for injectable contraception in the United States. Semin Reprod Med. Dec 2001;19(4):331-337.
Link to PubMed

37. Kaunitz AM. Current concepts regarding use of DMPA. J Reprod Med. Sep 2002;47(9 Suppl):785-789.
Link to PubMed

38. Keder LM, Rulin MC, Gruss J. Compliance with depot medroxyprogesterone acetate: a randomized, controlled trial of intensive reminders. Am J Obstet Gynecol. Sep 1998;179(3 Pt 1):583-585.
Link to PubMed

39. Khoiny FE. Use of depo-provera in teens. J Pediatr Health Care. Sep-Oct 1996;10(5):195-201.
Link to PubMed

40. Kim C, Seidel KW, Begier EA, Kwok YS. Diabetes and depot medroxyprogesterone contraception in Navajo women. Arch Intern Med. Jul 23 2001;161(14):1766-1771.
Link to PubMed

43. Mainwaring R, Hales HA, Stevenson K, et al. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives. Contraception. Mar 1995;51(3):149-153.
Link to PubMed

44. Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. Apr 2002;15(2):79-82.
Link to PubMed

45. Margulies R, Miller L. Increased depot medroxyprogesterone acetate use increases family planning program pharmaceutical supply costs. Contraception. Mar 2001;63(3):147-149.
Link to PubMed

46. Martin HL, Jr., Nyange PM, Richardson BA, et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis. Oct 1998;178(4):1053-1059.
Link to PubMed

47. Matson SC, Henderson KA, McGrath GJ. Physical findings and symptoms of depot medroxyprogesterone acetate use in adolescent females. J Pediatr Adolesc Gynecol. Feb 1997;10(1):18-23.
Link to PubMed

48. Middleman AB, Robertson LM, DuRant RH, Chiou V, Emans SJ. Use of hormonal methods of birth control among sexually active adolescent girls. J Pediatr Adolesc Gynecol. Nov 1997;10(4):193-198.
Link to PubMed

49. Morrison CS, Bright P, Wong EL, et al. Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections. Sex Transm Dis. Sep 2004;31(9):561-567.
Link to PubMed

50. Morroni C, Grams M, Tiezzi L, Westhoff C. Immediate monthly combination contraception to facilitate initiation of the depot medroxyprogesterone acetate contraceptive injection. Contraception. Jul 2004;70(1):19-23.
Link to PubMed

51. Nelson AL. Counseling issues and management of side effects for women using depot medroxyprogesterone acetate contraception. J Reprod Med. May 1996;41(5 Suppl):391-400.
Link to PubMed

52. O'Dell CM, Forke CM, Polaneczky MM, Sondheimer SJ, Slap GB. Depot medroxyprogesterone acetate or oral contraception in postpartum adolescents. Obstet Gynecol. Apr 1998;91(4):609-614.
Link to PubMed

53. Paul C, Skegg DC, Spears GF. Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer. Bmj. Sep 23 1989;299(6702):759-762.
Link to PubMed

54. Paul C, Skegg DC, Williams S. Depot medroxyprogesterone acetate. Patterns of use and reasons for discontinuation. Contraception. Oct 1997;56(4):209-214.
Link to PubMed

55. Pelkman C. Hormones and weight change. J Reprod Med. Sep 2002;47(9 Suppl):791-794.
Link to PubMed

56. Pelkman CL, Chow M, Heinbach RA, Rolls BJ. Short-term effects of a progestational contraceptive drug on food intake, resting energy expenditure, and body weight in young women. Am J Clin Nutr. Jan 2001;73(1):19-26.
Link to PDF

57. Penney G, Brechin S, Allerton L. FFPRHC Guidance (July 2005): The use of contraception outside the terms of the product licence. J Fam Plann Reprod Health Care. Jul 2005;31(3):225-241; quiz 242.
Link to PubMed

58. Petta CA, Faundes A, Dunson TR, et al. Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function. Fertil Steril. Nov 1998;70(5):817-820.
Link to PubMed

59. Petta CA, Faundes A, Dunson TR, et al. Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus. Fertil Steril. Feb 1998;69(2):252-257.
Link to PubMed

60. Phillips OP. New aspects of injectable contraception. Int J Fertil Womens Med. Jan-Feb 2001;46(1):31-36.
Link to PubMed

61. Pinkston Koenigs LM, Miller NH. The contraceptive use of Depo-Provera in U.S. adolescents. J Adolesc Health. May 1995;16(5):347-349.
Link to PubMed

62. Polaneczky M, Guarnaccia M, Alon J, Wiley J. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population. Fam Plann Perspect. Jul-Aug 1996;28(4):174-178.
Link to PubMed

63. Polaneczky M, Liblanc M. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents. J Adolesc Health. Aug 1998;23(2):81-88.
Link to PubMed

64. Potter LS, Dalberth BT, Canamar R, Betz M. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department. Contraception. Nov 1997;56(5):305-312.
Link to PubMed

65. Ratchanon S, Taneepanichskul S. Depot medroxyprogesterone acetate and basal serum prolactin levels in lactating women. Obstet Gynecol. Dec 2000;96(6):926-928.
Link to PubMed

66. Sangi-Haghpeykar H, Poindexter AN, 3rd, Bateman L, Ditmore JR. Experiences of injectable contraceptive users in an urban setting. Obstet Gynecol. Aug 1996;88(2):227-233.
Link to PubMed

67. Sangi-Haghpeykar H, Poindexter AN, 3rd, Moseley DC, Bateman L, Reid ED. Characteristics of injectable contraceptive users in a low-income population in Texas. Fam Plann Perspect. Sep-Oct 1995;27(5):208-211, 225.
Link to Full Text

68. Selo-Ojeme DO, Tillisi A, Welch CC. Anaphylaxis from medroxyprogesterone acetate. Obstet Gynecol. May 2004;103(5 Pt 2):1045-1046.
Link to PubMed

69. Sereepapong W, Chotnopparatpattara P, Taneepanichskul S, Markham R, Russell P, Fraser IS. Endometrial progesterone and estrogen receptors and bleeding disturbances in depot medroxyprogesterone acetate users. Hum Reprod. Mar 2004;19(3):547-552.
Link to PubMed

70. Shapiro S, Rosenberg L, Hoffman M, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol. Feb 15 2000;151(4):396-403.
Link to PubMed

71. Shulman LP, Nelson AL, Darney PD. Recent developments in hormone delivery systems. Am J Obstet Gynecol. Apr 2004;190(4 Suppl):S39-48.
Link to PubMed

72. Skegg DC, Noonan EA, Paul C, Spears GF, Meirik O, Thomas DB. Depot medroxyprogesterone acetate and breast cancer. A pooled analysis of the World Health Organization and New Zealand studies. Jama. Mar 8 1995;273(10):799-804.
Link to PubMed

73. Smit J, Gray A, McFadyen L, Zuma K. Counting the costs: comparing depot medroxyprogesterone acetate and norethisterone oenanthate utilisation patterns in South Africa. BMC Health Serv Res. 2001;1(1):4.
Link to PDF

74. Smit J, McFadyen L, Zuma K, Preston-Whyte E. Vaginal wetness: an underestimated problem experienced by progestogen injectable contraceptive users in South Africa. Soc Sci Med. Nov 2002;55(9):1511-1522.
Link to PubMed

75. Sneed R, Westhoff C, Morroni C, Tiezzi L. A prospective study of immediate initiation of depo medroxyprogesterone acetate contraceptive injection. Contraception. Feb 2005;71(2):99-103.
Link to PubMed

76. Sonnenberg FA, Burkman RT, Hagerty CG, Speroff L, Speroff T. Costs and net health effects of contraceptive methods. Contraception. Jun 2004;69(6):447-459.
Link to PubMed

77. Sorensen MB, Collins P, Ong PJ, et al. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation. Sep 24 2002;106(13):1646-1651.
Link to PDF

78. Templeman CL, Cook V, Goldsmith LJ, Powell J, Hertweck SP. Postpartum contraceptive use among adolescent mothers. Obstet Gynecol. May 2000;95(5):770-776.
Link to PubMed

79. Toh YC, Jain J, Rahnny MH, Bode FR, Ross D. Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 mL) contraceptive formulation in Asian women. Clin Ther. Nov 2004;26(11):1845-1854.
Link to PubMed

80. Varney SJ, Guest JF. Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK. Pharmacoeconomics. 2004;22(17):1141-1151.
Link to PubMed

81. Vercellini P, De Giorgi O, Oldani S, Cortesi I, Panazza S, Crosignani PG. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol. Aug 1996;175(2):396-401.
Link to PubMed

82. Westfall JM, Main DS. The contraceptive implant and the injectable: a comparison of costs. Fam Plann Perspect. Jan-Feb 1995;27(1):34-36.
Link to Full Text

83. Westfall JM, Main DS, Barnard L. Continuation rates among injectable contraceptive users. Fam Plann Perspect. Nov-Dec 1996;28(6):275-277.
Link to Full Text

84. Westhoff C, Truman C, Kalmuss D, et al. Depressive symptoms and Depo-Provera. Contraception. Apr 1998;57(4):237-240.
Link to PubMed

85. Williams HA, Watkins CE, Risby JA. Reproductive decision-making and determinants of contraceptive use in HIV-infected women. Clin Obstet Gynecol. Jun 1996;39(2):333-343.
Link to PubMed

86. Wilson E. Injectable contraception. Practitioner. Jan 1988;232(1441):32-36.
Link to PubMed

 

DEPO PROVERA AND BONE LOSS

1. Contraceptives and teens: what are the options? Contracept Technol Update. Sep 2000;21(9):109-111.
Link to PubMed

2. Bahamondes L, Perrotti M, Castro S, Faundes D, Petta C, Bedone A. Forearm bone density in users of Depo-Provera as a contraceptive method. Fertil Steril. May 1999;71(5):849-852.
Link to PubMed

3. Banks E, Berrington A, Casabonne D. Overview of the relationship between use of progestogen-only contraceptives and bone mineral density. Bjog. Dec 2001;108(12):1214-1221.
Link to PubMed

4. Berenson AB, Breitkopf CR, Grady JJ, Rickert VI, Thomas A. Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol. May 2004;103(5 Pt 1):899-906.
Link to PubMed

5. Berenson AB, Radecki CM, Grady JJ, Rickert VI, Thomas A. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol. Oct 2001;98(4):576-582.
Link to PubMed

6. Busen NH. Bone mineral density in adolescent women using depot medroxyprogesterone acetate. J Am Acad Nurse Pract. Feb 2004;16(2):57-62.
Link to PubMed

7. Busen NH, Britt RB, Rianon N. Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years. J Adolesc Health. Apr 2003;32(4):257-259.
Link to PubMed

8. Clark MK, Sowers MR, Nichols S, Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril. Dec 2004;82(6):1580-1586.
Link to PubMed

9. Cromer BA. Bone mineral density in adolescent and young adult women on injectable or oral contraception. Curr Opin Obstet Gynecol. Oct 2003;15(5):353-357.
Link to PubMed

10. Cromer BA. Effects of hormonal contraceptives on bone mineral density. Drug Saf. Mar 1999;20(3):213-222.
Link to PubMed

11. Cromer BA, Blair JM, Mahan JD, Zibners L, Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr. Nov 1996;129(5):671-676.
Link to PubMed

12. Cromer BA, Lazebnik R, Rome E, et al. Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. Am J Obstet Gynecol. Jan 2005;192(1):42-47.
Link to PubMed

13. Cromer BA, Stager M, Bonny A, et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health. Dec 2004;35(6):434-441.
Link to PubMed

14. Cundy T, Cornish J, Roberts H, Elder H, Reid IR. Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol. Oct 1998;92(4 Pt 1):569-573.
Link to PubMed

15. Cundy T, Cornish J, Evans MC, Roberts H, Reid IR. Recovery of bone density in women who stop using medroxyprogesterone acetate. Bmj. Jan 22 1994;308(6923):247-248.
Link to PubMed

16. Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid IR. Bone density in women receiving depot medroxyprogesterone acetate for contraception. Bmj. Jul 6 1991;303(6793):13-16.
Link to PubMed

17. Gbolade B, Ellis S, Murby B, Randall S, Kirkman R. Bone density in long term users of depot medroxyprogesterone acetate. Br J Obstet Gynaecol. Jul 1998;105(7):790-794.
Link to PubMed

18. Gordon CM, Nelson LM. Amenorrhea and bone health in adolescents and young women. Curr Opin Obstet Gynecol. Oct 2003;15(5):377-384.
Link to PubMed

19. Harkins GJ, Davis GD, Dettori J, Hibbert ML, Hoyt RA. Decline in bone mineral density with stress fractures in a woman on depot medroxyprogesterone acetate. A case report. J Reprod Med. Mar 1999;44(3):309-312.
Link to PubMed

20. Kaunitz AM. Long-acting injectable contraception with depot medroxyprogesterone acetate. Am J Obstet Gynecol. May 1994;170(5 Pt 2):1543-1549.
Link to PubMed

21. Kaunitz AM. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians. Int J Fertil Womens Med. Mar-Apr 1998;43(2):73-83.
Link to PubMed

22. Kaunitz AM. Long-acting hormonal contraception: assessing impact on bone density, weight, and mood. Int J Fertil Womens Med. Mar-Apr 1999;44(2):110-117.
Link to PubMed

23. Lara-Torre E, Edwards CP, Perlman S, Hertweck SP. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. Feb 2004;17(1):17-21.
Link to PubMed

24. Lloyd T, Lin HM, Eggli DF, Dodson WC, Demers LM, Legro RS. Adolescent Caucasian mothers have reduced adult hip bone density. Fertil Steril. Jan 2002;77(1):136-140.
Link to PubMed

25. Mark S. Premenopausal bone loss and depot medroxyprogesterone acetate administration. Int J Gynaecol Obstet. Dec 1994;47(3):269-272.
Link to PubMed

26. Mehta S. Bone loss, contraception and lactation. Acta Obstet Gynecol Scand. Apr 1993;72(3):148-156.
Link to PubMed

27. Merki-Feld GS, Neff M, Keller PJ. A prospective study on the effects of depot medroxyprogesterone acetate on trabecular and cortical bone after attainment of peak bone mass. Bjog. Jul 2000;107(7):863-869.
Link to PubMed

28. Merki-Feld GS, Neff M, Keller PJ. A 2-year prospective study on the effects of depot medroxyprogesterone acetate on bone mass-response to estrogen and calcium therapy in individual users. Contraception. Feb 2003;67(2):79-86.
Link to PubMed

29. Orr-Walker BJ, Evans MC, Ames RW, Clearwater JM, Cundy T, Reid IR. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol (Oxf). Nov 1998;49(5):615-618.
Link to PubMed

30. Ott SM, Scholes D, LaCroix AZ, Ichikawa LE, Yoshida CK, Barlow WE. Effects of contraceptive use on bone biochemical markers in young women. J Clin Endocrinol Metab. Jan 2001;86(1):179-185.
Link to PDF

31. Paiva LC, Pinto-Neto AM, Faundes A. Bone density among long-term users of medroxyprogesterone acetate as a contraceptive. Contraception. Dec 1998;58(6):351-355.
Link to PubMed

32. Perrotti M, Bahamondes L, Petta C, Castro S. Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate. Fertil Steril. Sep 2001;76(3):469-473.
Link to PubMed

33. Rome E, Ziegler J, Secic M, et al. Bone biochemical markers in adolescent girls using either depot medroxyprogesterone acetate or an oral contraceptive. J Pediatr Adolesc Gynecol. Dec 2004;17(6):373-377.
Link to PubMed

34. Scholes D, Lacroix AZ, Ott SM, Ichikawa LE, Barlow WE. Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol. Feb 1999;93(2):233-238.
Link to PubMed

35. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med. Feb 2005;159(2):139-144.
Link to PubMed

36. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women. Contraception. Feb 2004;69(2):99-104.
Link to PubMed

37. Sowers MF, Scholl T, Harris L, Jannausch M. Bone loss in adolescent and adult pregnant women. Obstet Gynecol. Aug 2000;96(2):189-193.
Link to PubMed

38. Taneepanichskul S, Intaraprasert S, Theppisai U, Chaturachinda K. Bone mineral density in long-term depot medroxyprogesterone acetate acceptors. Contraception. Jul 1997;56(1):1-3.
Link to PubMed

39. Westhoff C. Bone mineral density and DMPA. J Reprod Med. Sep 2002;47(9 Suppl):795-799.
Link to PubMed

40. Westhoff C. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes. J Reprod Med. May 1996;41(5 Suppl):401-406.
Link to PubMed